Photo from wikipedia
Compared to conventional aspirin therapy, ticagrelor did not improve vein graft patency 1 year after coronary bypass surgery (CABG) in the ticagrelor antiplatelet therapy to reduce graft events and thrombosis… Click to show full abstract
Compared to conventional aspirin therapy, ticagrelor did not improve vein graft patency 1 year after coronary bypass surgery (CABG) in the ticagrelor antiplatelet therapy to reduce graft events and thrombosis (TARGET) trial. However, it is unknown whether ticagrelor may impact graft patency long‐term following surgery.
Keywords:
target trial;
ticagrelor;
coronary bypass
Journal Title: Journal of Cardiac Surgery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Cardiac Surgery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!